Quantitative Xylazine Measurement in ED

Quantitative Xylazine Measurement Among Non-Fatal Opioid Overdose Patients in the Emergency Department

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06949605

Enrollment

Registered

2025-04-29

Start date

2025-04-01

Completion date

2026-02-28

Last updated

2026-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Overdose, Substance Use Disorders

Keywords

Opioid, Xylazine, Substance Use

Brief summary

Quantitative Xylazine Measurement Among Non-Fatal Opioid Overdose (OD) Patients in the Emergency Department (ED)

Detailed description

Xylazine, a veterinary medication and alpha-2 agonist drug with clinical effects including prolonged sedation and skin/soft tissue wounds, has been increasingly detected with fentanyl in the illicit opioid supply. Due to its rapid emergence, limited knowledge exists regarding xylazine's health effects. In this proposed research, Dr. Love will measure xylazine and its metabolites in blood and urine samples using laboratory and point-of-care assays. Working at two New York City emergency departments, Dr. Love will collect waste serum and urine from opioid overdose patients to measure xylazine and its metabolite concentrations. The researcher will also perform qualitative assessment of urine samples with xylazine test strips to characterize urine xylazine detection using a harm reduction tool.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* ED patient * Opioid OD (both NPS and non-NPS) * Availability of waste blood specimens for analysis * Availability of waste urine specimens for analysis

Exclusion criteria

\- Children under 18

Design outcomes

Primary

Measure	Time frame	Description
Xylazine Concentration in Blood	6 months	Concentration of Xylazine in blood as determined by lab.

Secondary

Measure	Time frame	Description
Xylazine Strip Specificity and Sensitivity	6 months	Measuring Xylazine test strip specificity and sensitivity using excess urine samples.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJennifer Love, MD, MS

Icahn School of Medicine

Outcome results